Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista colombiana de Gastroenterología
Print version ISSN 0120-9957On-line version ISSN 2500-7440
Abstract
Terapia cuádruple con furazolidona como tratamiento de rescate para la infección por Helicobacter pylori. Rev Col Gastroenterol [online]. 2003, vol.18, n.4, pp.222-227. ISSN 0120-9957.
Therapeutic failures are often seen in the treatment of H. Pylori (HP) infection; different studies show that this can happen in 10 to 20% of cases. The principal factors involved in the lack of success are: primary resistance to antibiotics and the non compliance to treatment. The objective of the present work is to evaluate the efficacy and tolerance of a quadruple formulation with furazolidone in patients with persistent infection after several trials to eradicate HP. Materials and methods. This is a prospective work done with adult patients aged 18 to 75 years, to whom a persistent HP infection was found at least six weeks after one or several treatments for its eradication. All of them received oral treatment with the following scheme during 10 days: omeprazole, 20 mg fasting and before supper, tetracycline chlorhydrate 500 mg four times a day, amoxicillin, 500 mg four times a day, and furazolidone, 100 mg four times a day (OTAF 10). The outcome variable was the eradication of HP: absence of the infection proven by the three methods used: urea respiratory test, histopathology and fast urease test. This variable was analysed on an "intention to treat" basis. Patients taking at least 80% of each drug were included in the "per protocol" analysis. The eradication rate was expressed as a percentage with confidence intervals of 95% Results. Ninety patients were studied, 62% women. Age average was 44,3 ± 12.9 years. HP was eradicated as treatment intention in 81.1%, CI 95%, 71.2 to 83.3%; and 83.9% by protocol, CI 95%, 73.7 to 90%. Adverse side effects were present in 20% of patients. Only three patients withdrew because of headaches, diarrhea and rash respectively. Conclusion: OTAF 10 is an acceptable strategy as an empirical rescue treatment after treatment failures for its 80% efficacy, low cost, tolerance and safety.